SG11201806372UA - Nucleic acid conjugate - Google Patents
Nucleic acid conjugateInfo
- Publication number
- SG11201806372UA SG11201806372UA SG11201806372UA SG11201806372UA SG11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA SG 11201806372U A SG11201806372U A SG 11201806372UA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- acid conjugate
- independently
- formula
- oligonucleotide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/10—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/02—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton
- C07C247/04—Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016016707 | 2016-01-29 | ||
PCT/JP2017/003249 WO2017131236A1 (ja) | 2016-01-29 | 2017-01-30 | 核酸複合体 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201806372UA true SG11201806372UA (en) | 2018-08-30 |
Family
ID=59398306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201806372UA SG11201806372UA (en) | 2016-01-29 | 2017-01-30 | Nucleic acid conjugate |
Country Status (11)
Country | Link |
---|---|
US (1) | US10745700B2 (ja) |
EP (1) | EP3409780B1 (ja) |
JP (1) | JP6853193B2 (ja) |
KR (1) | KR20180103166A (ja) |
CN (1) | CN108699558B (ja) |
AU (1) | AU2017213404A1 (ja) |
CA (1) | CA3012967A1 (ja) |
ES (1) | ES2858090T3 (ja) |
SG (1) | SG11201806372UA (ja) |
TW (1) | TWI733751B (ja) |
WO (1) | WO2017131236A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2952757T3 (es) * | 2016-06-30 | 2023-11-03 | Kyowa Kirin Co Ltd | Complejo de ácidos nucleicos |
US11963974B2 (en) | 2017-03-10 | 2024-04-23 | National Center For Child Health And Development | Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia |
JPWO2018199340A1 (ja) | 2017-04-28 | 2020-03-12 | 協和キリン株式会社 | オリゴヌクレオチド誘導体またはその塩 |
TW201920668A (zh) * | 2017-08-02 | 2019-06-01 | 日商協和醱酵麒麟有限公司 | 核酸複合體 |
TW201909925A (zh) * | 2017-08-02 | 2019-03-16 | 日商協和醱酵麒麟有限公司 | 核酸複合體 |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11958878B2 (en) | 2018-03-09 | 2024-04-16 | Daiichi Sankyo Company, Limited | Therapeutic agent for glycogen storage disease type IA |
WO2019243391A1 (en) * | 2018-06-21 | 2019-12-26 | F. Hoffmann-La Roche Ag | Hybridizing all-lna oligonucleotides |
WO2020038377A1 (zh) | 2018-08-21 | 2020-02-27 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
JP7376952B2 (ja) * | 2018-09-30 | 2023-11-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | siRNA複合体及びその調製方法と使用 |
EP3873486A4 (en) * | 2018-11-02 | 2022-10-19 | Arbutus Biopharma Corporation | BIVALENT TARGETED CONJUGATES |
US20220127605A1 (en) * | 2018-11-30 | 2022-04-28 | Kyowa Kirin Co., Ltd. | Nucleic acid conjugate |
JPWO2021049504A1 (ja) | 2019-09-10 | 2021-03-18 | ||
CA3150890A1 (en) * | 2019-09-17 | 2021-03-25 | Philip Stewart Low | Fibroblast activation protein (fap)-targeted imaging and therapy of cancers and other fibrotic and inflammatory diseases |
WO2023143374A1 (zh) * | 2022-01-30 | 2023-08-03 | 成都凌泰氪生物技术有限公司 | 一种配体、其制备方法及应用 |
WO2023187760A1 (en) * | 2022-04-01 | 2023-10-05 | Genevant Sciences Gmbh | Mannose-targeted compositions |
CN116444589B (zh) * | 2023-06-15 | 2023-09-19 | 北京悦康科创医药科技股份有限公司 | 新型GalNAc化合物及其硫代寡核苷酸缀合物和偶联方法 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469158B1 (en) | 1992-05-14 | 2002-10-22 | Ribozyme Pharmaceuticals, Incorporated | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5977343A (en) | 1992-05-14 | 1999-11-02 | Ribozyme Pharmaceuticals, Inc. | Synthesis, deprotection, analysis and purification of RNA and ribozymes |
US5804683A (en) | 1992-05-14 | 1998-09-08 | Ribozyme Pharmaceuticals, Inc. | Deprotection of RNA with alkylamine |
ATE227342T1 (de) | 1993-09-02 | 2002-11-15 | Ribozyme Pharm Inc | Enzymatische nukleiksaüre die nicht-nukleotide enthaltet |
US5889136A (en) | 1995-06-09 | 1999-03-30 | The Regents Of The University Of Colorado | Orthoester protecting groups in RNA synthesis |
AU1039397A (en) * | 1995-11-22 | 1997-06-27 | Johns Hopkins University, The | Ligands to enhance cellular uptake of biomolecules |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6111086A (en) | 1998-02-27 | 2000-08-29 | Scaringe; Stephen A. | Orthoester protecting groups |
US20080199960A1 (en) | 2004-05-13 | 2008-08-21 | Juliano Rudolph L | Methods for the Delivery of Oligomeric Compounds |
EP4223299A3 (en) | 2007-12-04 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
ES2370638B1 (es) | 2010-03-05 | 2012-11-16 | Universidad De Castilla La Mancha | Dendrimeros como vehiculos no virales para terapia genica |
AU2011343664B2 (en) * | 2010-12-17 | 2015-10-08 | Arrowhead Pharmaceuticals, Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
CN103649311A (zh) * | 2011-06-03 | 2014-03-19 | 国立大学法人北海道大学 | 寡核苷酸衍生物、包含寡核苷酸衍生物的治疗用医药组合物及诊断用医药组合物、以及miRNA机能抑制用寡核苷酸衍生物 |
SG10201912170WA (en) | 2011-11-18 | 2020-02-27 | Alnylam Pharmaceuticals Inc | Rnai Agents, Compositions And Methods Of Use Thereof For Treating Transthyretin (TTR) Associated Diseases |
EP3453762B1 (en) | 2012-05-02 | 2021-04-21 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
TWI595885B (zh) | 2012-05-02 | 2017-08-21 | 喜納製藥公司 | 包含四galnac之新穎結合物及傳送寡核苷酸之方法 |
CA2873772A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics Inc. | Compositions and methods for modulating bdnf expression |
JP2016522674A (ja) | 2012-05-16 | 2016-08-04 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
KR20150083920A (ko) * | 2012-11-15 | 2015-07-20 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 항 apob 안티센스 접합체 화합물 |
AU2014259750B2 (en) | 2013-05-01 | 2019-02-28 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
AU2014287002A1 (en) | 2013-07-11 | 2016-02-11 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide-ligand conjugates and process for their preparation |
WO2015042447A1 (en) | 2013-09-20 | 2015-03-26 | Isis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
JP6482475B2 (ja) | 2014-01-07 | 2019-03-13 | レナセラピューティクス株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
ES2952757T3 (es) * | 2016-06-30 | 2023-11-03 | Kyowa Kirin Co Ltd | Complejo de ácidos nucleicos |
-
2017
- 2017-01-30 JP JP2017563894A patent/JP6853193B2/ja active Active
- 2017-01-30 KR KR1020187024809A patent/KR20180103166A/ko unknown
- 2017-01-30 CN CN201780008949.8A patent/CN108699558B/zh not_active Expired - Fee Related
- 2017-01-30 WO PCT/JP2017/003249 patent/WO2017131236A1/ja active Application Filing
- 2017-01-30 SG SG11201806372UA patent/SG11201806372UA/en unknown
- 2017-01-30 EP EP17744465.0A patent/EP3409780B1/en active Active
- 2017-01-30 ES ES17744465T patent/ES2858090T3/es active Active
- 2017-01-30 CA CA3012967A patent/CA3012967A1/en active Pending
- 2017-01-30 AU AU2017213404A patent/AU2017213404A1/en not_active Abandoned
- 2017-01-30 US US16/073,112 patent/US10745700B2/en active Active
- 2017-02-02 TW TW106103567A patent/TWI733751B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2858090T3 (es) | 2021-09-29 |
JP6853193B2 (ja) | 2021-03-31 |
CA3012967A1 (en) | 2017-08-03 |
AU2017213404A1 (en) | 2018-09-20 |
CN108699558A (zh) | 2018-10-23 |
US20190055558A1 (en) | 2019-02-21 |
US10745700B2 (en) | 2020-08-18 |
JPWO2017131236A1 (ja) | 2018-11-22 |
EP3409780A1 (en) | 2018-12-05 |
TWI733751B (zh) | 2021-07-21 |
EP3409780B1 (en) | 2021-01-20 |
TW201730200A (zh) | 2017-09-01 |
WO2017131236A1 (ja) | 2017-08-03 |
CN108699558B (zh) | 2021-12-07 |
EP3409780A4 (en) | 2019-09-25 |
KR20180103166A (ko) | 2018-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201806372UA (en) | Nucleic acid conjugate | |
NZ630800A (en) | Methods of preparing substituted nucleotide analogs | |
WO2015073575A3 (en) | Residualizing linkers and uses thereof | |
PH12020550132A1 (en) | Novel enantiomers of a series of antiviral compounds | |
IN2015DN01061A (ja) | ||
PH12018501642B1 (en) | Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof | |
AU2018301662A1 (en) | Purified 2,5-furandicarboxylic acid pathway products | |
CA3010551A1 (en) | Pyrrolobenzodiazepine conjugates | |
WO2014207567A3 (en) | Process for the preparation of abiraterone and intermediates thereof | |
WO2016099727A3 (en) | Ligand components, associated reaction products, activated reaction products, hydrosilylation catalysts and hydrosilylation curable compositions including the ligand components, and associated methods for preparing same | |
MX2016002217A (es) | Compuestos con actividad pesticida. | |
MX2016004393A (es) | Derivados de carboxamida como compuestos pesticidas. | |
WO2017035319A8 (en) | Methods for treatment of polycystic kidney disease | |
MX350430B (es) | Proceso para preparar compuestos acido 4-amino-5-bifenil-4-il-2-hi droximetil-2-metil-pentanoico. | |
WO2013121279A3 (en) | Process to prepare ertapenem | |
WO2015111004A3 (en) | Improved process for the preparation of chlorophenyl trifluoroethanone | |
WO2014097272A3 (en) | Process for the preparation of (s,s)-6-benzloctahydro-1 h-pyrrolo[3,4-b]pyridine,an intermediate of azabicyclopyridine derivatives | |
PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
MY186779A (en) | Nucleic acid derivative having immunostimulatory activity | |
WO2014030173A3 (en) | Improved process for preparation of atazanavir bisulfate | |
WO2017046816A3 (en) | Process for the preparation of derivatives of benzodioxole | |
WO2017004172A8 (en) | Total synthesis of shishijimicin a and analogs thereof | |
IN2015DN02699A (ja) | ||
WO2016005474A8 (en) | Site selective conjugation of an oligonucleotide conjugate or a small molecule to a metal binding protein | |
GB201912021D0 (en) | Methods, products & Uses relating thereto |